CLDF Title
Home | Contact Us | Bookmark
Embassy of Education  
Slide Library Webcasts Abstract Library LiverQ Academy National Conference
Lilly's Cyramza fails in liver cancer trial

Lilly's Cyramza fails in liver cancer trial

By Reuters Staff

(Reuters) - Eli Lilly and Co's recently approved stomach cancer drug Cyramza failed to prolong the lives of patients with advanced liver cancer in a late-stage trial, the drugmaker said on Wednesday.

Patients enrolled in the trial previously had failed to benefit from standard chemotherapy for liver cancer.

"Liver cancer is a very difficult-to-treat tumor type and no Phase III study has been able to demonstrate improved survival in the second-line setting," Lilly said in a release.

Although Cyramza failed to meet the primary survival goal of the trial, Lilly said meaningful improvements were seen in secondary goals of the study, including tumor shrinkage and how long it took for patient conditions to worsen after treatment.

Moreover, Lilly said some specific populations seemed especially to benefit from treatment with its drug.

Lilly said it plans to discuss the overall results with health regulators, given the favorable secondary trends seen in the 565-patient international trial and the absence of any approved second-line treatments for liver cancer.

Cyramza also failed in an earlier study to improve outcomes for patients with breast cancer.

But the drug has proven effective in a late-stage trial against the most common form of lung cancer, and Lilly is also testing it against colorectal cancer.



Be the first to know about our latest upcoming programs and events!


Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2023 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.